Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHGX1N)

• Drug Name: C75 Drug Info
• Synonyms: C75 trans; C75 (trans); 191282-48-1; 3-Carboxy-4-octyl-2-methylenebutyrolactone; CHEMBL449993; trans-4-Carboxy-5-octyl-3-methylenebutyrolactone; Fatty Acid Synthase Inhibitor, C75; (+)-trans-C75; C75 (racemic); SCHEMBL3007085; CTK8E7727; MolPort-005-933-439; HMS3649D16; ZINC2009913; BCP11074; HY-12364A; BDBM50256128; trans-Tetrahydro-3-methylene-2-oxo-5-n-octyl-4-furancarboxylic acid; AKOS015960616; VC30664; CS-3561; AC-11808; RT-011885; SR-01000946704; SR-01000946704-1; J-012362; UNII-8E9A8CTX2H component VCWLZDVWHQVAJU-NEPJUHHUSA-

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 4248455
  ChEBI ID: CHEBI:95108
  CAS Number: CAS 218137-86-1
  TTD Drug ID: DMHGX1N

Molecule-Related Drug Atlas

Drug(s) Targeting Fatty acid synthase (FASN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cerulenin	DM6N4PR	Weight loss	MG43.5	Approved	[2]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[3]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[4]
TVB-2640	DM19GUH	Astrocytoma	2A00.0Y	Phase 2	[5]
FAS1	DMAX2EW	Fungal infection	1F29-1F2F	Preclinical	[6]
FSA2	DMLNRCI	Fungal infection	1F29-1F2F	Preclinical	[6]
MORIN	DM2OGZ5	Discovery agent	N.A.	Investigative	[3]
biochanin A	DM0HPWY	Discovery agent	N.A.	Investigative	[3]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[3]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Carnitine O-palmitoyltransferase I (CPT1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levacecarnine hci	DMJBOCR	Cognitive impairment	6D71	Approved	[7]
Perhexiline	DMINO7Z	Angina pectoris	BA40	Approved	[8]
SDZ-CPI-975	DM70MJQ	Diabetic complication	5A2Y	Discontinued in Phase 1	[9]
Etomoxir	DM3BHN1	Heart failure	BD10-BD13	Terminated	[10]
DB-200	DMTXPSB	Psoriasis vulgaris	EA90	Terminated	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carnitine O-palmitoyltransferase I (CPT1B)	TTDL0NY	CPT1B_HUMAN	Activator	[1]
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[1]

References

• [1] C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502.
• [2] Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91.
• [3] Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
• [4] Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.
• [5] Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118.
• [6] Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
• [7] Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74.
• [8] Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97.
• [9] Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8.
• [10] Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
• [11] Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7.